This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

Threshold Pharmaceuticals (THLD), Clovis Oncology (CLVS) and Newlink Genetics (NLNK) are among Celgene's competitors pursuing development of their own pancreatic cancer drugs.

Celgene's ongoing phase III study compares the combination of Abraxane and gemcitabine versus gemcitabine and a placebo with a primary endpoint of overall survival. The study is being led by a pancreatic cancer Dream Team of oncologists and some doctors are already prescribing Abraxane off label to pancreatic cancer patients, according to reports posted on various patient advocacy web sites. The results reported by some of these patients is anecdotal, of course, but does appear to be consistent with the strong results reported in the Abraxane phase II studies.

Make no mistake, the outcome of the Abraxane phase III study in pancreatic cancer remains high risk. But what I like most about the Celgene CVR at $TK is that the market is hardly pricing in success at all.

Each holder of the Celgene CVR receives a pro-rata share of $300 million in cash, paid if FDA approves Abraxane for pancreatic cancer with a survival claim in the label. If the approval occurs before April 1, 2013, Celgene pays an additional $100 million.

Additionally, Celgene CVR holders will receive an ongoing royalty tied to Abraxane sales that starts at 2.5 % for annualized sales of $1 billion and scales higher. Abraxane sales today are annualizing at about $450 million, but pancreatic cancer sales, alone, could exceed $1 billion.

Some investors may prefer to play the Abraxane pancreatic cancer trial event by owning Celgene itself. I own the Celgene CVR because of the favorable risk-reward. I would expect the CVR to trade closer to $7.50 (from $TK today) if Abraxane improves overall survival in the pancreatic cancer trial. The risk is the CVR could become almost worthless if the pancreatic cancer trial fails. Results from the study are expected late this year or early next.

Silverman is long Celgene CVR.

Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs